spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  desvenlafaxine 

 HSMN NewsFeed - 10 Mar 2017
Mylan Launches Generic Pristiq(R) Tablets
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 15 May 2008
Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
Biopharmaceuticals
 HSMN NewsFeed - 12 Mar 2008
More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Dec 2007
New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
Biopharmaceuticals
 HSMN NewsFeed - 15 Oct 2007
Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
Biopharmaceuticals
 HSMN NewsFeed - 24 Jul 2007
Wyeth Receives Approvable Letter from FDA for PRISTIQ for the Treatment of Vasomotor Symptoms Associated with Menopause
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Jan 2007
Wyeth Receives Approvable Letter From FDA for Pristiq (Desvenlafaxine Succinate) for the Treatment of Major Depressive Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Jun 2006
Wyeth Submits Two New Drug Applications for Women's Health Therapies
Biopharmaceuticals
 HSMN NewsFeed - 25 May 2006
Desvenlafaxine Succinate (DVS-233) Phase 3 Data Show Significant Improvement in Symptoms of Depression in Adult Patients Versus Placebo
Biopharmaceuticals
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.